drugset
drugset / Trial / NCT01363804

A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects

NCT01363804 ↗

Phase 1 Completed 30 enrolled AVEO Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to evaluate the effect of rifampin on the Pharmacokinetic (PK) profile of tivozanib.

Timeline

Start
2011-05
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Tivozanib Small molecule 1.5 mg —

Indications

No indication recorded.